NCT06318871View on ClinicalTrials.gov

Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 28, 2024

Primary Completion Date

December 28, 2025

Study Completion Date

May 28, 2030

Conditions
Renal CarcinomaRenal Cell CarcinomaUrothelial CarcinomaChromophobe Renal Cell CarcinomaTranslocation Renal Cell Carcinoma
Interventions
BIOLOGICAL

Cytokine Induced Memory-like Natural Killer (CIML NK) Cells

Autologous, cytokine induced memory-like natural killer cells, via intravenous (into the vein) infusion per protocol.

DRUG

Interleukin-2 (IL-2)

Interleukin-2 (aldesleukin, IL-2) will be used to support natural killer cell proliferation and activity

Trial Locations (2)

02215

RECRUITING

Brigham and Women's Hospital, Boston

RECRUITING

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Kidney Cancer Association

UNKNOWN

lead

Dana-Farber Cancer Institute

OTHER